Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective

MeSH terms

• Alzheimer Disease* / diagnosis
• Alzheimer Disease* / drug therapy
• Amyloid beta-Peptides / antagonists & inhibitors
• Antibodies, Monoclonal, Humanized* / administration & dosage
• Antibodies, Monoclonal, Humanized* / adverse effects
• Antibodies, Monoclonal, Humanized* / economics
• Brain* / diagnostic imaging
• Brain* / pathology
• Decision Making
• Dose-Response Relationship, Drug*
• Drug Approval / methods
• Humans
• Infusions, Intravenous / methods
• Magnetic Resonance Imaging / methods
• Nootropic Agents / administration & dosage
• Nootropic Agents / adverse effects
• Nootropic Agents / economics
• Plaque, Amyloid / diagnostic imaging*
• Positron-Emission Tomography / methods
• Product Surveillance, Postmarketing
• Randomized Controlled Trials as Topic / methods
• Treatment Outcome
• United States